The U.S. Food and Drug Administration has approved a new treatment for triple negative breast cancer

, the U.S. Food and Drug Administration has accelerated approval of treatment for adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients mustat least twice before taking the serpentic anti-thrombotic enzyme.
"Metastasis triple negative breast cancer is an invasive breast cancer with limited treatment options. Chemotherapy has been the main treatment for triple negative breast cancer. "Today, we approved new targeted treatments," said Dr. Richard Pazdur, director of the U.S. Food and Drug Administration's Center of Excellence in Oncology and acting director of the U.S. Food and Drug Administration's Office of Oncology and Diseases. There is a lot of interest in finding new drugs to help treat metastasis triple negative breast cancer. Today's approval offers a new option for patients who have already tried two previous treatments."Trodelvy is a Trop-2-guided drug complex of antibodies and topological isomer inhibitors, which means that the drug targets Trap-2 subjects that help cancer grow, divide, and spread, and is connected to topological isomer inhibitors, a toxic compound to cancer cells. About 2 out of every 10 breast cancer diagnoses worldwide are tri-negative. Triple negative breast cancer is a type of breast cancer that is detected as negative by estrogen, progesterone, and human skin growth factor 2 (HER2) proteins. Therefore, triple negative breast cancer does not respond to hormone therapy drugs or drugs for HER2."As part of the FDA's ongoing positive commitment to responding to the new coronavirus pandemic, we will continue to focus on cancer patients who are vulnerable to the disease," pazdur said. We will continue to accelerate the development of oncology products at this critical time. The application was approved more than a month ahead of the FDA's target date -- an example of a commitment. Our staff will continue to meet with drug developers, academic researchers, and patient advocates to facilitate coordinated review of cancer treatment.
the U.S. Food and Drug Administration approved Paitway based on the results of a clinical trial of 108 patients with metastasis trisomy breast cancer who had previously been treated for metastasis at least twice.snake anti-thrombotic enzyme is based on total efficiency (ORR), which reflects the percentage of patients with a certain tumor reduction. The ORR was 33.3 per cent and the median reaction duration was 7.7 months. Inpatients who responded to snake antithrombotic enzymes, 55.6% maintained a response for 6 months or more and 16.7% maintained a response for 12 months or more.Prescription drug information includes a boxed warning to health care professionals and patients about the risk of severe neutral granulocyte reduction (abnormally low white blood cell levels) and severe diarrhea. Healthcare professionals should regularly monitor a patient's blood cell count during treatment withsnake antithrombolytic enzymes and consider treating patients with a treatment called granulocyte collection stimulation factor (G-CSF), which stimulates bone marrow to produce white blood cells called granulocytes and stem cells and release them into the bloodstream to help prevent infection, and should also initiate anti-infection treatment for patients with hypothermal neural reduction (when white blood cells are abnormally low)., health care professionals should monitor patients with diarrhoea and provide fluids, electrolytes and supportive care medications as needed. Due to reduced neutral granulocytes or diarrhea, medication may need to be stopped, dose reduced, or permanently stopped. Walking can cause allergic reactions, including severe allergic reactions. Infusion-related reactions should be monitored and health professionals should stop intravenous injections in the event of a serious or life-threatening reaction. If the patient experiences nausea or vomiting while taking this product, the health care provider should use anti-spitting prevention treatment to prevent nausea and vomiting. Patients with reduced activity of urinary diphosphate glucosaldehyde acid transferase 1A1 (UGT1A1) had an increased risk of developing a reduced risk of neutral granulocytes after startingsnake anti-hydrant therapy.most common side effects in patients taking this product are nausea, reduced neutral granulocytes, diarrhea, fatigue, anemia, vomiting, hair loss (hair loss), constipation, decreased appetite, rash and abdominal pain. Pregnant women should not take birth control pills because they can cause harm to a developing fetus or newborn.
U.S. Food and Drug Administration recommends that health care professionals inform women of childbearing age to use effective methods of contraception during and within six months of taking the pill. Male patients with potential reproductive partners should also use effective methods of contraception during and within three months of the last dose. Tedvey's accelerated approval allowed the U.S. Food and Drug Administration to approve drugs for serious illnesses to meet unsettly medical needs, based on a reason to predict the outcome of a patient's clinical benefit. Further clinical trials are needed to verify and describe the clinicalof snake anti-embolase.
The U.S. Food and Drug Administration approved the application for a priority review and breakthrough treatment name that will accelerate the development and review of drugs designed to treat serious illnesses when preliminary clinical evidence suggests that the drug may be substantially better than existing treatments. Tedway was also awarded the title of "Fast Track", which speeds up the review of drugs that treat serious illnesses and meet unseeded medical needs. The U.S. Food and Drug Administration has approved the immunology company's vaccine. （cyy123.com）